ABSTRACT
Metal halide perovskites offer ample opportunities to develop advanced optoelectronic devices. This work showcases that the integration of metal halide perovskites into metal oxide nanoshells with controllable interior cavities can enable water-vapor-responsive dual-mode switching of fluorescence and structural color. Through a ship-in-a-bottle method to introduce a controlled amount of CsPbBr3 into MnO2 nanoshells, we have designed CsPbBr3@MnO2 yolk-shell nanostructures, which can uptake a defined amount of water to exhibit rapid (less than 1 s) and reversible (≥100 cycles) responses in both fluorescence on-off and color change when exposed to dynamic water vapor. These responses originate from the water-triggered phase transformation of CsPbBr3 to CsPb2Br5 and the structural color change of the MnO2 shell. The altered electronic and bonding structure at the oxide-halide interface, rapid water accumulation in the yolk-shell cavity, and protective effect of the oxide shell facilitate the reversible transformations. The response characteristics of the yolk-shell nanostructures have been further demonstrated in fabricating patterned films capable of multiple fluorescence/structural color responses, highlighting their potential for applications in advanced anticounterfeiting and encryption.
ABSTRACT
ABCB1 and ABCG2 are the important ATP-binding cassette (ABC) transporters associated with multidrug resistance (MDR). Herein, we designed a series of imidazo[1,2-a]pyridine derivatives as dual-target inhibitors of ABCB1 and ABCG2 through the scaffold hopping strategy. Compound Y22 displayed potential efflux function inhibitory toward both ABCB1 and ABCG2 (reversal fold: ABCB1 = 8.35 and ABCG2 = 2.71) without obvious cytotoxicity. Y22 also enhanced the potency of antiproliferative drugs in vitro. Mechanistic studies demonstrated that Y22 slightly suppressed ATPase activity but did not affect the protein expression of ABCB1 or ABCG2. Notably, Y22 exhibited negligible CYP3A4 inhibition and enhanced the antiproliferative activity of adriamycin in vivo by restoring the sensitivity of resistant cells. Thus, Y22 may be effective clinically in combination with common chemotherapy agents. In summary, Y22 is a potential dual-target inhibitor that reverses MDR by blocking the efflux function of ABCB1 and ABCG2.
